<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794740</url>
  </required_header>
  <id_info>
    <org_study_id>TFR-X0002-101</org_study_id>
    <nct_id>NCT02794740</nct_id>
  </id_info>
  <brief_title>Study of X0002 Following Escalating Single and Multiple Doses Administered as Topical Application in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin XinChen-Techfields Pharma Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin XinChen-Techfields Pharma Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To evaluate the safety and tolerability of escalating single and multiple doses of X0002&#xD;
      administered as a topical application.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To characterize the single and and multiple pharmacokinetics of escalating doses of X0002 and&#xD;
      its active metabolite ibuprofen as a topical application.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">March 29, 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Single Dose Arms:6days;Multiple Doses Arms:17days</time_frame>
    <description>Adverse Event; Vital Signs; Physical Examination; Laboratory Examination; Electrocardiograph; Skin Irritation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])</measure>
    <time_frame>Single Dose Arms:0-120hours;Multiple Doses Arms:0-120hours post-dose;11th day pre-dose;12th day 0-120 hours post-dose.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters(Area Under Curve [AUC])</measure>
    <time_frame>Single Dose Arms:0-120hours;Multiple Doses Arms:0-120hours post-dose;11th day pre-dose;12th day 0-120 hours post-dose.</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>X0002 First Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X0002 Second Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Second Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X0002 Third Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Third Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X0002 Fourth Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Subjects,Single Dose,Once,Double-Blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Fourth Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 Subjects,Single Dose,Once,Double-Blind.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>X0002</intervention_name>
    <description>External Spray</description>
    <arm_group_label>X0002 First Dose</arm_group_label>
    <arm_group_label>X0002 Fourth Dose</arm_group_label>
    <arm_group_label>X0002 Second Dose</arm_group_label>
    <arm_group_label>X0002 Third Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>External Spray</description>
    <arm_group_label>Placebo Fourth Dose</arm_group_label>
    <arm_group_label>Placebo Second Dose</arm_group_label>
    <arm_group_label>Placebo Third Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gender: male or female, each sex ratio does no less 1/3;&#xD;
&#xD;
          -  Were between the ages of 18 and 45 years, inclusive. General condition is will;&#xD;
&#xD;
          -  Were between the Body Mass Index (BMI) of 19-28, inclusive; BMI=Weight(kg)/Height2&#xD;
             (m2); Weight≥50kg (female) and 60kg (male);&#xD;
&#xD;
          -  Nearly half of the year, no child care program and agree to take effective measures to&#xD;
             contraception during the study period, blood pregnancy test of women in childbearing&#xD;
             age was negative;&#xD;
&#xD;
          -  Vital signs (measurement seated after resting 5 minutes) in the following range&#xD;
&#xD;
               1. Temperature (auxiliary temperature): 35.0-37.0℃&#xD;
&#xD;
               2. Systolic Pressure: 90-139mmHg&#xD;
&#xD;
               3. Diastolic Pressure: 60-89mmHg&#xD;
&#xD;
               4. sphygmus: 55-99bpm&#xD;
&#xD;
          -  Subjects to fully understand the purpose, properties, method and reactions may occur&#xD;
             of test drug trials. Were capable of giving informed consents voluntarily, and agreed&#xD;
             to comply with the requirements of clinical protocols.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary disease in important organs;&#xD;
&#xD;
          -  Mental or physical disability;&#xD;
&#xD;
          -  Familial hereditary diseases;&#xD;
&#xD;
          -  Clinically significant history of Electrocardiograph (ECG) abnormality, or&#xD;
             Electrocardiograph (ECG) abnormality in the Screening or Baseline;&#xD;
&#xD;
          -  Clinically significant abnormities in laboratory examination:&#xD;
&#xD;
               1. Clinically significant abnormities in Liver Function Tests, for example aspartate&#xD;
                  aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase&#xD;
                  (ALP) or bilirubin.&#xD;
&#xD;
               2. Creatinine and Urea Nitrogen exceeded the upper limit of normal, or significant&#xD;
                  abnormities in urinary composition.&#xD;
&#xD;
               3. Clinically significant abnormities of routine blood test, for example anemia,&#xD;
                  Leukocyte reduced, Platelet significantly reduced,etc.( Combined with adverse&#xD;
                  events in the laboratory to determine the value of abnormal).&#xD;
&#xD;
               4. Abnormality of immunology, including HIV(human immunodeficiency virus) antibody&#xD;
                  positive, Hepatitis B surface antigen (HBsAg) positive, HCV(hepatitis C virus)&#xD;
                  antibody positive or Syphilis antibody positive.&#xD;
&#xD;
          -  Drug abusers,or drug screening positive;&#xD;
&#xD;
          -  Who was addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit&#xD;
             = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or&#xD;
             not smoking and drinking in the test period;Test positive for nicotine or breath test&#xD;
             positive for alcohol(&gt;0.0mg/100ml);&#xD;
&#xD;
          -  Took any drug long excretory phase that may affect the study, or in the past 3 months&#xD;
             participated in any drug clinical trials;&#xD;
&#xD;
          -  Entering the group 4 weeks ago used any prescription drugs ,or used any over the&#xD;
             counter (OTC) drugs within 2 weeks (vitamins, herbal tonics, etc.), or before entering&#xD;
             the group within 2 weeks took excessively food that effected drug metabolizing&#xD;
             enzymes, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but&#xD;
             must record report in case report form (CRF）;&#xD;
&#xD;
          -  A history of gastrointestinal bleeding or peptic ulcers, drugs allergy for aspirin or&#xD;
             hypersensitivity to aspirin or other NSAIDs (Non-Steroidal Antiinflammatory Drugs), or&#xD;
             a history of asthma or other allergic-type reactions after taking aspirin or other&#xD;
             NSAIDs(Non-Steroidal Antiinflammatory Drugs); A history of intolerance or&#xD;
             hypersensitivity to ibuprofenamine hydrochloride or any excipients or to the diluent&#xD;
             ethanol;&#xD;
&#xD;
          -  Donation or blood collection, or acute loss of blood during the 3 months prior to&#xD;
             screening( more than 400ml);&#xD;
&#xD;
          -  Had skin diseases wound or other symptom, investigators consider that maybe unsafe for&#xD;
             subjects or effect of evaluation for application sites;&#xD;
&#xD;
          -  There was a clinical significance history of allergy for drugs or food, or atopic&#xD;
             allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug allergy for&#xD;
             test drugs or similar drugs;&#xD;
&#xD;
          -  Lactating women, pregnant women or unable to take effective contraceptive measures;&#xD;
&#xD;
          -  Researchers believed that participants not suitable to take the test for other&#xD;
             factors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin Xinchen-Techfields Pharma Co. Ltd</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

